BB:MITRA Mithra Pharmaceuticals S.A

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics primarily for treating women's fertility, contraception, and menopause needs in Belgium, the Netherlands, Luxembourg, and internationally. Its two lead development candidates include Estelle, which is in a Phase III clinical trial, a fifth generation oral contraceptive in Europe and North America under the E4 Freedom name; and Donesta, which is in a Phase II clinical trial that is used for a new generation of hormone therapy with the oral administration of Estetrol (E4) for vasomotor menopausal symptoms relief. The company's research and development pipeline consists of three therapeutics comprising Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. It provides products in polymeric forms, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals S.A. was founded in 1999 and is headquartered in Liège, Belgium.

21.60 EUR
As of 01/14/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  06/30/2015
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   892,236,800 EUR
Current dividend yield:   0.00%
Sedol:      BYP79G2

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy